Effect of Watermelon on Cardiometabolic Health
Effect of Watermelon Consumption on Cardiometabolic Health and Whole-Body Antioxidant Capacity
Effect of Watermelon Consumption on Cardiometabolic Health and Whole-Body Antioxidant Capacity
Sponsor study identifier
interventional
22
1 country
1
Study Start
April 1, 2026
Actual (reported)Primary Completion
September 1, 2027
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Study Completion
September 1, 2027
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
The purpose of this study is to determine whether consumption of 355 ml of watermelon juice will:
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
September 1, 2027
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Click on a node to explore related trials.
Some registry-reported names shown below are not yet linked in this graph.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
May 28, 2025
Actual (reported)June 5, 2025
Actual (reported)April 1, 2026
Actual (reported)September 1, 2027
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
September 1, 2027
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Postprandial blood pressure
To determine the acute and chronic effects of WMJ consumption on cardiometabolic health, specifically focusing on postprandial blood pressure. Previous studies showed that watermelon extract improved blood pressure management in subjects with prehypertension and hypertension and reduced arterial stiffness in postmenopausal women. Postprandial blood pressure response is recently identified to be the most sensitive postprandial clinical feature in predicting subclinical atherosclerosis. However, no study has evaluated the effect of watermelon on postprandial blood pressure. Blood pressure will be measured in mm/Hg.
Baseline and Week 4
Postprandial heart rate
Will be measured in beats per minute.
Baseline and 4 weeks.
Postprandial pulse wave velocity
Will be measured in meters/second.
Baseline and 4 weeks.
Postprandial nitric oxide (NO)
Baseline and 4 weeks.
Postprandial glucose
Baseline and 4 weeks.
Postprandial blood lipids/lipoproteins (LDL cholesterol, HDL cholesterol, total cholesterol, triglycerides).
Baseline and 4 weeks.
Postprandial insulin
Baseline and 4 weeks.
Postprandial C-peptide
Baseline and 4 weeks.
Minimal Erythema Dose (MED)
Baseline and week 4.
Blood and urinary malondialdehyde (MDA) concentrations
Baseline and 4 weeks.
Acute (postprandial) as well as chronic (4 weeks) effects of WMJ consumption will be evaluated. To evaluate acute effects participants will consume a liquid meal test together with WMJ at the beginning of the intervention phase. In addition, the same liquid meal test will be consumed with only WMJ at the end of the intervention phase to assess whether drinking the juice for 4 weeks prior had any effects on postprandial responses.
Participants will consume placebo beverage + liquid meal test at baseline. They will then consume watermelon juice daily for 4 weeks. Watermelon juice + liquid meal test will be consumed at endpoint.
WMJ will be purchased from a commercially available brand. The liquid meal test will be in the form of the Boost nutritional drink (8 fl.oz., vanilla flavor), which is commercially available.
The placebo beverage made of water and sugar will match the sugar content provided in 355 ml of WMJ (approximately 10-20 g). The liquid meal test will be in the form of the Boost nutritional drink (8 fl.oz., vanilla flavor), which is commercially available.
UCLA Center for Human Nutrition
Los Angeles, California, 90095, United States
Zhaoping Li, MD, PhD
University of California, Los Angeles
First Submitted
May 28, 2025
First Posted
June 5, 2025
Study Start
April 1, 2026
Actual (reported)Primary Completion
September 1, 2027
EstimatedResveratrol Effects on Inflammatory Biomarkers and Cardiometabolic Parameters.
Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.
Contact the study team to confirm eligibility.
Planned date reported by the registry; this milestone is not confirmed as achieved.
Study Completion
September 1, 2027
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Last Updated
July 31, 2026
Record last verified: 2026-07
Data analysis will be performed in-house.
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: